文献速递膀胱癌与上尿路尿路上皮癌

新辅助化疗后隐匿淋巴结阳性膀胱癌患者预后差

Poor prognosis of bladder cancer patients with occult lymph node metastases treated with neoadjuvant chemotherapy.
PubMed 文献 · BJU Int · 2018-05-04

该研究基于2000—2010年1484例根治性膀胱切除加盆腔淋巴结清扫的膀胱尿路上皮癌患者,分析198例临床非转移但术后淋巴结阳性者。比较新辅助化疗后淋巴结阳性32例与辅助化疗后淋巴结阳性49例,发现新辅助化疗组3年无复发生存率为26%,辅助化疗组为60%,前者复发与癌特异性死亡风险显著更高。

要点

  • 新辅助化疗后淋巴结阳性患者3年无复发生存率仅26%,显著低于辅助化疗后淋巴结阳性者的60%。
  • 多因素校正病理分期和淋巴结密度后,新辅助化疗组复发风险HR 3.11、癌特异性死亡风险HR 3.05,均显著升高。
  • 此类高危患者应考虑三明治化疗方案或新药方案,并在临床试验分层中予以重视。

核心结论

  • 新辅助化疗后根治性膀胱切除发现淋巴结阳性的患者预后差,显著劣于后续接受辅助化疗的淋巴结阳性患者。

研究设计与样本

  • 回顾性分析2000—2010年1484例接受根治性膀胱切除加盆腔淋巴结清扫的膀胱尿路上皮癌患者,其中198例为临床非转移(cN0M0)但术后淋巴结阳性。
  • 比较新辅助化疗后淋巴结阳性32例与辅助化疗后淋巴结阳性49例,采用Cox比例风险模型,并设计敏感性分析校正新辅助化疗患者至根治性膀胱切除的额外时间。

主要发现

  • 淋巴结阳性新辅助化疗患者3年无复发生存率估计为26%,淋巴结阳性辅助化疗患者为60%。
  • 单因素分析中新辅助化疗组复发风险HR 2.86(95%CI 1.58-5.19,P=0.001),癌特异性死亡风险HR 2.50(95%CI 1.34-4.65,P=0.004)。
  • 多因素校正病理分期和淋巴结密度后,复发风险HR 3.11(95%CI 1.59-6.07,P=0.001),癌特异性死亡风险HR 3.05(95%CI 1.46-6.35,P=0.003)。
  • 敏感性分析同样显示新辅助化疗后淋巴结阳性患者结局更差。

关键数值与推荐

  • 淋巴结阳性新辅助化疗患者3年无复发生存率26%,淋巴结阳性辅助化疗患者60%。
  • 单因素复发HR 2.86(95%CI 1.58-5.19,P=0.001),癌特异性死亡HR 2.50(95%CI 1.34-4.65,P=0.004)。
  • 多因素复发HR 3.11(95%CI 1.59-6.07,P=0.001),癌特异性死亡HR 3.05(95%CI 1.46-6.35,P=0.003)。

临床怎么用

  • 对根治性膀胱切除术后发现淋巴结阳性且术前接受新辅助化疗的患者,应视为高危人群加强随访与复发监测。
  • 此类患者可考虑三明治化疗方案或新药方案,并在临床试验设计与分层中单独考虑。

局限性

  • 为回顾性比较,新辅助化疗组与辅助化疗组样本量不对称(32例对49例),未接受围手术期化疗者年龄更大且合并症更多,存在选择偏倚。
  • 敏感性分析仅用于校正新辅助化疗患者至根治性膀胱切除的额外时间,仍需前瞻性验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To characterise the outcomes of neoadjuvant chemotherapy (NAC) pre-treated patients found to be lymph node (LN)-positive at the time of radical cystectomy and pelvic lymph node dissection (RC/PLND) for urothelial carcinoma of the bladder (UCB). PATIENTS AND METHODS: Of 1484 patients treated with RC/PLND for UCB from 2000 to 2010, we analysed 198 patients with clinically non-metastatic (cN0M0) muscle-invasive UCB who were found to be LN-positive at RC/PLND. As patients not receiving perioperative chemotherapy were significantly older and comorbid, we compared LN-positive patients previously treated with NAC (32 patients) to LN-positive patients treated with adjuvant chemotherapy (AC, 49 patients) using Cox proportional hazards models. A sensitivity analysis was designed to account for the additional time to RC in NAC patients. RESULTS: The 3-year recurrence-free survival estimate for LN-positive NAC patients was 26%, compared with 60% for LN-positive AC patients. LN-positive patients treated with NAC had significantly higher risks of disease recurrence and cancer-specific mortality in univariate analyses (hazard ratio [HR] 2.86, 95% confidence interval [CI] 1.58-5.19, P = 0.001 and HR 2.50, 95% CI 1.34-4.65, P = 0.004, respectively) and multivariable analyses adjusting for pathological stage and LN density (HR 3.11, 95% CI 1.59-6.07, P = 0.001 and HR 3.05, 95% CI 1.46-6.35, P = 0.003, respectively). Sensitivity analyses similarly demonstrated worse outcomes for NAC pre-treated LN-positive patients. CONCLUSION: LN-positive patients previously treated with NAC have a poor prognosis, significantly worse than LN-positive patients subsequently treated with AC, and should be considered for protocols using sandwich chemotherapy approaches or novel agents. These results should be considered in the interpretation of and stratification for clinical trials.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Cha EK, Sfakianos JP, Sukhu R, et al. Poor prognosis of bladder cancer patients with occult lymph node metastases treated with neoadjuvant chemotherapy. BJU Int. 2018. PMID: 29633530. doi:10.1111/bju.14242

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。